Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 251-256

  Nishida, Hirofumi ^a   Sato, Toshiaki ^a   Nomura, Momoko ^a   Miyazaki, Masaru ^a   Nakaya, Haruaki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cardioprotection; Diabetes mellitus; Glimepiride; Phosphatidylinositol 3 kinase; Postconditioning

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GLIMEPIRIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRIPHENYLTETRAZOLIUM; SULFONYLUREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; HEART DISEASE; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; ANIMAL; DRUG EFFECT; HEART INFARCTION; IN VITRO STUDY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; MYOCARDIAL INFARCTION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SULFONYLUREA COMPOUNDS;

EID: 65449133560     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08202FP     Document Type: Article

References (23)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287:2570-2581.
2. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20:704-708.
3. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA myocardial infarction register study group. Diabetes Care. 1998;21:69-75.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. available data in humans and clinical applications. Diabetes Metab. 2003;29:207-222.
6. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:531-537.
7. Sato T, Nishida H, Miyazaki M, Nakaya H. Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev. 2006;22:341-347.
8. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111-3116.
9. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006;70:200-211.
10. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. Postconditioning the human heart. Circulation. 2005;112:2143-2148.
11. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
12. Ueba H, Kuroki M, Hashimoto S, Umemoto T, Yasu T, Ishikawa SE, et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis. 2005;183:35-39.
13. Nishida H, Sato T, Miyazaki M, Nakaya H. Infarct size limitation by adrenomedullin: protein kinase A but not PI3- kinase is linked to mitochondrial KCa channels. Cardiovasc Res. 2008;77:398-405.
14. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44:1103-1110.
15. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res. 2006;70:264-273.
16. Salani B, Repetto S, Cordera R, Maggi D. Glimepiride activates eNOS with a mechanism Akt but not caveolin-1 dependent. Biochem Biophys Res Commun. 2005;335:832-835.
17. Pharmacokinetic Data. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The pharmacological basis of therapeutics, 11th ed, New York: McGraw-Hill; 2006. p. 1831.
18. Klimt CR, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19:747-830.
19. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976-979.
20. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439-446.
21. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22:477-482.
22. Johnsen SP, Monster TBM, Olsen ML, Thisted H, McLaughlin JK, Sorensen HT, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13:134-140.
23. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91:979-989.